Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback